Clement Colin I

Standalone iStent Trabecular Micro-bypass Glaucoma Surgery: A Systematic Review and Meta-Analysis.

The results from these studies support the independent effect of the iStent trabecular bypass devices on IOP and medication burden over a duration of follow-up of up to 5 years.

Comparative study of 2-year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery.

Twenty-four-month outcomes showed sustained IOP reduction with a good safety profile for both groups.

Comparison of bleb morphology between trabeculectomy and deep sclerectomy using a clinical grading scale and anterior segment optical coherence tomography.

Significant differences in bleb morphology, correlating with improved IOP outcomes in TRAB eyes compared with DS eyes in patients with open-angle glaucoma, were showed by both the IBAGS and AS-OCT.

Association Between Prior Selective Laser Trabeculoplasty and Phaco-iStent Inject Efficacy.

In this observational study, prior SLT was associated with an increased risk of failure after phaco-iStent inject surgery.

Longitudinal outcomes of iStent inject with cataract surgery compared with cataract surgery alone: real-world data from the Fight Glaucoma Blindness registry.

Real-world outcomes from the FGB registry at 12 months show that phacoemulsification combined with iStent inject has a higher efficacy and reduced need for secondary IOP-lowering surgery compared with phacoemulsification alone.

Outcomes of chronic hypotony following trabeculectomy.